Drug use evaluation of recombinant human coagulation factor VIIa based on weighted TOPSIS method

Published on Apr. 27, 2023Total Views: 641 times Total Downloads: 228 times Download Mobile

Author: Guo-Quan CHEN ^1, ² Li JIANG ^2, ³  Jin-Hua ZHANG ^2, ⁴

Affiliation: 1. Department of Pharmacy, Affiliated Jinhua Hospital, Medical College of Zhejiang University, Jinhua 321000, Zhejiang Province, China 2. Department of Pharmacy, Affiliated Union Hospital, Fujian Medical University, Fuzhou 350001, China 3. Department of Pharmacy, Minhou County People’s Hospital, Fuzhou 350119, China 4. Department of Pharmacy, Fujian Provincial Maternity and Children’s Hospital, Fuzhou 350001, China

Keywords: Weighted TOPSIS method Recombinant human coagulation factor Ⅶa Drug use evaluation

DOI: 10.19960/j.issn.1005-0698.202304004

Reference: Guo-Quan CHEN, Li JIANG, Jin-Hua ZHANG.Drug use evaluation of recombinant human coagulation factor Ⅶa based on weighted TOPSIS method[J].Yaowu Liuxingbingxue Zazhi,2023, 32(4):384-390.DOI: 10.19960/j.issn.1005-0698.202304004.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Objective To establish the evaluation criteria for the use of recombinant human coagu-lation factor Ⅶa (rFⅦa), and to evaluate the rationality of clinical practice of rFⅦa.

Methods The rFⅦa evaluation criteria was established based on literature survey and expert consultation. 73 cases of rFⅦa archived medical records in the Affiliated Union Hospital of Fujian Medical University and evaluated by weighted TOPSIS method were collected.

Results Of the 73 cases, 4 cases (5.48%) had relative proximity (Ci)≥80%, 55 cases (75.34%) had 60%≤Ci<80%, and 14 cases (19.18%) had Ci<60%. The main unrea-sonable evaluation indicators were indications (68.5%), dose and duration (63.0%) and adverse effect monitoring (43.8%).

Conclusion The DUE criteria of rFⅦa is practical and scientific. The application of rFⅦa for tumor patients is basically reasonable according to the weighted TOPSIS method. However, there are still some problems, mainly in terms of abusive indications for use, low dosage and lack of coagulation indicators monitoring.

Full-text

Please download the PDF version to read the full text: download

References

1.Hwang CL, Yoon K. Multiple attribute decision making[M].Berlin, Heidelberg: Springer, 1981: 58-191.

2.李育梅,邵建国.应用TOPSIS法综合评价医院医疗工作质量的变化[J].第二军医大学学报, 2008, 29(12): 1531-1533. [Li YM, Shao JG. Application of TOPSIS method to comprehensive evaluation of changes in hospital medical work quality[J]. Academic Journal of Naval Medical University, 2008, 29(12): 1531-1533.] DOI: 10.3724/SP.J.1008.2008.01531.

3.吴玉娇,张晶,熊浩.基于AHP-TOPSIS法的围手术期预防使用质子泵抑制药合理性评价[J].中国药师, 2021, 24(7): 310-314. [Wu YJ, Zhang J, Xiong H. Evaluation of the rationality of proton pump inhibitor use in peri-operative prophylaxis based on AHP-TOPSIS method[J]. China Pharmacist, 2021, 24(7): 310-314.] DOI: 10.19962/j.cnki.issn1008-049X.2021.07.019.

4.程乾生. 属性层次模型AHM——一种新的无结构决策方法[J].北京大学学报(自然科学版), 1998, (1): 12-16. [Cheng GS. Attribute hierarchy model AHM: A new unstructured decision making method[J]. Acta Scientiarum Naturalium Universitatis Pekinensis, 1998, (1): 12-16.]DOI: 10.13209/j.0479-8023.1998.003.

5.方煜,胡明,陈麒骏,等. 2013年中国药学会药事管理专业委员会年会暨“医药安全与科学发展”学术论坛论文集（下册）[C]. 北京: 中国药学会, 2013: 308-313.

6.董恒进, 陈洁. 临床药物利用评价[J]. 中华医院管理杂志, 1998, 14(8): 10-12. [Dong HJ, Chen J. Evaluation of clinical drug utilization[J]. Chinese Journal of Hospital Administration, 1998, 14(8): 10-12.] DOI: 10.3760/cma.j.issn.1000-6672.1998.08.104.

7.Hedner U. Recombinant activated factor Ⅶ: 30 years of research and innovation[J]. Blood Reviews, 2015, 29: S4-S8. DOI: 10.1016/S0268-960X(15)30002-3.

8.Monroe DM, Roberts HR, Hoffman M. Platelet procoagulant complex assembly in a tissue fac-tor-initiated system[J]. Br J Haematol, 1994, 88(2): 364-371. DOI: 10.1111/j.1365-2141.1994.tb05032.x.

9.Monroe DM, Hoffman M, Oliver JA, et al. Platelet activity of high‐dose factor VIIa is independent of tissue factor[J]. Br J Haematol, 1997, 99(3): 542-547. DOI: 10.1046/j.1365-2141.1997.4463256.x.

10.中华医学会血液学分会血栓与止血学组,中国血友病协作组.获得性血友病A诊断与治疗中国指南(2021年版)[J].中华血液学杂志, 2021, 42(10): 793-799. DOI: 10.3760/cma.j.issn.0253-2727.2021.10.001.

11.中华医学会血液学分会血栓与止血学组,中国血友病协作组. 血友病治疗中国指南(2020年版)[J]. 中华血液学杂志, 2020, 41(4): 265-271. DOI: 10.3760/cma.j.issn.0253-2727.2020.04.001.

12.围术期出凝血管理麻醉专家共识协作组. 围术期出凝血管理麻醉专家共识[J].中华麻醉学杂志, 2020, 40(9): 1042-1053. DOI: 10.3760/cma.j.cn 131073.20200808. 00904.

13.昝昕, 胡鑫, 王婕, 等. 出凝血功能障碍相关性脑出血中国多学科诊治指南[J]. 中国急救医学, 2021, 41(8): 647-660. [Zan X, Hu X, Wang J, et al. Chinese guidelines for diagnosis and treatment of cerebral hemorrhage associated with coagulation dysfunction[J]. Chinese Journal of Critical Care Medicine, 2021, 41(8): 647-660.] DOI: 10.3969/j.issn.1002-1949.2021.08.002.

14.Nevo S, Enger C, Hartley E, et al. Acute bleeding and thrombocytopenia after bone marrow trans-plantation[J]. Bone Marrow Transplant, 2001, 27(1): 65-72. DOI: 10.1038/sj.bmt.1702717.

15.高永,王玖,石德文.加权TOPSIS法综合评价在Excel中的实现[J]. 中国卫生统计, 2007, 24(4): 428-429. [Gao Y, Wang J, Shi DW. Implementation of weighted TOPSIS comprehensive evaluation in Excel[J]. Chinese Journal of Health Statistics, 2007, 24(4): 428-429.] DOI: 10.3969/j.issn.1002-3674.2007.04.035.

16.中华医学会血液学分会. 造血干细胞移植后出血并发症管理中国专家共识(2021年版)[J].中华血液学杂志, 2021, 42(4): 276-280. DOI: 10.3760/cma.j.issn.0253- 2727.2021.04.002.

17.Tang Y, Wu Q, Wu X, et al. Use of recombinant factor VIIa in uncontrolled gastrointestinal bleeding after hematopoietic stem cell transplantation among patients with thrombocytopenia[J]. Pak J Med Sci, 2015, 31(6): 1389-1393. DOI: 10.12669/pjms.316.8357.

18.Eller P, Pechlaner C, Wiedermann CJ. Ineffective off-label use of recombinant activated factor Ⅶ in a case of bone-marrow transplantation-related gastrointestinal bleeding[J]. Thromb J, 2006, 4(1): 1-4. DOI: 10.1186/1477-9560-4-1.

19.刘葳,薛峰,刘晓帆,等.重组人凝血因子Ⅶa治疗血液病患者出血的临床疗效分析[J].中华血液学杂志, 2017, 38(5): 410-414. [Liu W, Xue F, Liu XF, et al. Clinical analysis of recombinant human coagulation factor Ⅶ in the treatment of haemorrhage in patients with hematological diseases[J]. Chinese Journal of Hema-tology, 2017, 38(5): 410-414.] DOI: 10.3760/cma.j.issn.0253-2727.2017.05.011.

20.Kenet G, Walden R, Eldad A, et al. Treatment of traumatic bleeding with recombinant factor VIIa[J]. Lancet, 1999, 354(9193): 1879. DOI: 10.1016/S0140-6736(99)05155-7.

21.Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients[J]. Pathophysiol Haemost Thromb, 2002, 32(Suppl 1): 41-46. DOI: 10.1159/000057301.

22.Yilmaz AA, Yalcin S, Serdaroglu H, et al. Prophylaxis with recombinant-activated factor Ⅶ (rFⅦa) for minimally invasive surgery in a patient with congenital factor Ⅶ deficiency: a case report with a sin-gle-low dose of rFⅦa[J]. Blood Coagul fibrinolysis, 2008, 19(7): 693-695. DOI: 10.1097/MBC.0b013e3282f544ff.

23.Goodnough LT, Levy JH. The judicious use of recombinant factor Ⅶa[J].Semin Thromb Hemost, 2016, 42(2): 125-132. DOI: 10.1055/s-0035-1569068.

24.王海平, 陈国权, 邱树胜, 等. 阿哌沙班药物利用评价标准建立和应用[J]. 药物流行病学杂志, 2022, 31(11): 749-755. [Wang HP, Chen GQ, Qiu SS, et al. Establishment and application of evaluation criteria for drug utilization of Apixaban[J]. Chinese Journal of Pharmacoepidemiology, 2022, 31(11): 749-755.] DOI: 10.19960/j.cnki.issn1005-0698.2022.11.006.

25.曾艳,厉泉汝,王海莲,等. 2016~2020年中国九城市老年失眠患者镇静催眠类药物使用趋势分析[J].药物流行病学杂志, 2022, 31(5): 321-327. [Zeng Y, Li QR, Wang HL, et al. Trend analysis of sedative-hypnotic drug use among elderly patients with insomnia in nine cities in China from 2016 to 2020[J]. Chinese Journal of Pharmacoepidemiology, 2022, 31(5): 321-327.] DOI: 10.19960/j.cnki.issn1005-0698.2022.05.006.